Bevacizumab

(Avastin®)

Avastin®

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 100 mg/4 mL [25 mg/mL] or 400 mg/16 mL [25 mg/mL])
Drug ClassVascular endothelial growth factor (VEGF) inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil based chemotherapy for first- or second-line treatment
  • Indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidineirinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen
  • Indicated for the treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment
  • Indicated for the treatment of recurrent glioblastoma in adults
  • Indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa
  • Indicated for the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan
  • Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection
  • Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens
  • Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease
  • Indicated for the treatment of hepatocellular Carcinoma (HCC): in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 127 systematic review(s)/meta-analysis(es). [1-126]
  • In meningioma patients, the mean progression-free survival (PFS) and overall survival (OS) were 19.1 ± 4.7 months and 23.9 ± 8.4 months, respectively, with six-month, twelve-month, and twenty-four-month PFS rates at 0.80, 0.66, and 0.25, and OS rates at 0.89, 0.86, and 0.48, respectively; the response rate was 0.33 (95% confidence interval (CI): 0.14–0.60).
  • In hepatocellular carcinoma (HCC), sorafenib combined with bevacizumab showed improved outcomes in Asian populations compared to other therapies, such as lenvatinib or atezolizumab with bevacizumab, following initial treatment with sorafenib.
  • For non-small cell lung cancer (NSCLC), the combination of pemetrexed with bevacizumab was associated with improved overall survival (hazard ratio (HR) = 0.87) and PFS (HR = 0.63), although there was an increase in grade ≥3 adverse events with the combination.
  • In epithelial ovarian cancer, combining bevacizumab with carboplatin and paclitaxel significantly improved PFS (HR: 0.73; 95% CI: 0.58, 0.92; p = 0.008) compared to carboplatin and paclitaxel alone.
  • In HCC, common adverse events with treatments including bevacizumab were hypertension, non-central nervous system (CNS) bleeding, thromboembolic events, gastrointestinal perforation, pain, and proteinuria.
  • For epithelial ovarian cancer, bevacizumab combined with carboplatin and paclitaxel resulted in a higher incidence of adverse events, notably hypertension, non-CNS bleeding, thromboembolic events, gastrointestinal perforation, pain, and proteinuria, compared to chemotherapy alone.
  • In NSCLC, the combination of bevacizumab and pemetrexed led to an increase in grade ≥3 adverse events with an odds ratio of 2.15, indicating higher toxicity compared to pemetrexed monotherapy.
  • In colorectal cancer, bevacizumab combined with chemotherapy was associated with an increase in grade ≥3 adverse events, including hypertension and gastrointestinal perforation, compared to monotherapy.
  • In meningioma patients, bevacizumab showed high efficacy in refractory, high-grade, or neurofibromatosis-associated cases, with the study population consisting of 47.9% male patients.
  • In HCC, sorafenib combined with bevacizumab yielded better outcomes in Asian populations, and in NSCLC, the combination of lenvatinib with programmed cell death protein 1 (PD-1) and locoregional therapy (LRT) demonstrated higher conversion to surgery rates and increased objective response rates in certain subgroups.

Product Monograph / Prescribing Information

Document TitleYearSource
Avastin (bevacizumab) Prescribing Information.2022Genentech, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis2024Neurosurgical Review
Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies2024International Journal of Molecular Sciences
A Systematic Review and Meta-Analysis on the Effectiveness of Radiotherapy and Temozolomide Treatment With or Without Bevacizumab in Patients With Glioblastoma Multiforme2024Neurology India
Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients-A Systematic Review and Meta-Analysis2024Pharmaceuticals (basel, Switzerland)
Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis2024Bmc Cancer
Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study2024Journal of Cardiothoracic Surgery
Comparison of systemic treatments for previously treated patients with unresectable colorectal liver metastases: a systematic review and network meta-analysis2024Frontiers in Oncology
Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials2024Bmc Cancer
Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review2024Health Economics Review
Impact of bevacizumab on clinical outcomes and its comparison with standard chemotherapy in metastatic colorectal cancer patients: a systematic review and meta-analysis2024Journal of Pharmaceutical Policy and Practice
Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis2024Bmc Cancer
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis2024Liver Cancer
Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy2024International Journal of Gynaecology and Obstetrics: the Official Organ of the
Chordoma Genetic Aberrations and Targeted Therapies Panorama: A Systematic Literature Review2024Journal of Clinical Medicine
The efficacy of adjunctive mitomycin C and/or anti-VEGF agents on glaucoma tube shunt drainage device surgeries: a systematic review2024Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von
The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis2024Therapeutic Advances in Gastroenterology
Comparative analysis of bevacizumab and LITT for treating radiation necrosis in previously radiated CNS neoplasms: a systematic review and meta-analysis2024Journal of Neuro-oncology
Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials2024Frontiers in Pharmacology
A Network Meta-analysis of the Efficacy of Drug Therapy in First-line Treatment of Advanced Hepatocellular Carcinoma2024Journal of Gastrointestinal and Liver Diseases : Jgld
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review2024The Oncologist
Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis2024Therapeutic Advances in Medical Oncology
Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis2024Bmc Gastroenterology
Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: A systematic review and meta-analysis in anorectal medicine2024International Wound Journal
Correction: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis2024International Journal of Clinical Pharmacy
Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis2023Frontiers in Oncology
Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta-analysis2023Cancer Medicine
Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis2023Liver Cancer
Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence2023Health Science Reports
Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis2023Therapeutic Advances in Chronic Disease
Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis2023Frontiers in Oncology
Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis2023Clinical and Experimental Hepatology
Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review2023Current Oncology (toronto, Ont.)
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis2023Eclinicalmedicine
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials2023European Journal of Medical Research
Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials2023Annals of Medicine
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis2023Frontiers in Pharmacology
Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis2023Bmc Cancer
Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review2023Frontiers in Pharmacology
Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis2023Medicine
Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis2023International Journal of Colorectal Disease
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer2023The Cochrane Database of Systematic Reviews
Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs2023Frontiers in Oncology
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis2023Plos One
Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis2023Frontiers in Oncology
First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis2023Liver Cancer
Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis2023Frontiers in Pharmacology
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis2023Current Oncology (toronto, Ont.)
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis2022Frontiers in Immunology
Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis2022Frontiers in Oncology
Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: A systematic review of randomized controlled trials2022Medicine
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer2022Frontiers in Immunology
Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis2022Therapeutic Advances in Medical Oncology
First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review2022Current Oncology (toronto, Ont.)
Bevacizumab-Induced Hypertension as a Potential Physiological Clinical Biomarker for Improved Outcomes in Patients With Recurrent Glioblastoma Multiforme: A Systematic Review2022Cureus
Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies2022Cancer Treatment and Research Communications
Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab2022Frontiers in Pharmacology
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis2022Cancers
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis2022International Journal of Gynecological Cancer : Official Journal of the
A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art2022Frontiers in Oncology
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer2022Cancer Treatment Reviews
Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis2022Discover Oncology
Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis2022Cancer
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials2022Bmj Open
Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis2022International Journal of Environmental Research and Public Health
Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis2022Cancers
Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis2022Oncology Research and Treatment
Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis2022Frontiers in Pharmacology
Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis2022Translational Cancer Research
The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects2022International Journal of Molecular Sciences
Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis2022Frontiers in Public Health
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis2022Bmc Cancer
Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis2022Journal of Clinical Medicine
Systemic Treatments for Advanced Small Bowel Adenocarcinoma: A Systematic Review2022Cancers
Clinical trials targeting neurofibromatoses-associated tumors: a systematic review2022Neuro-oncology Advances
A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer2022Scientific Reports
Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis2022Healthcare (basel, Switzerland)
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer2022The Cochrane Database of Systematic Reviews
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States2022Journal of Medical Economics
Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis2022Oncology Research and Treatment
Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials2022Cancers
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies2022Clinical Cancer Research : an Official Journal of the American Association for
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline2022Journal of Clinical Oncology : Official Journal of the American Society of
Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis2022Thoracic Cancer
The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials2022Journal of Clinical Pharmacy and Therapeutics
Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario2021Canadian Liver Journal
First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials2021Frontiers in Oncology
Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis2021Jama Network Open
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review2021World Journal of Gastrointestinal Oncology
Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis2021Frontiers in Oncology
Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients2021International Journal of Clinical Oncology
Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis2021Cancers
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis2021The Cochrane Database of Systematic Reviews
Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer2021Cancer Control : Journal of the Moffitt Cancer Center
The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials2021Biomed Research International
Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis2021Medicine
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis2021Medicine
Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis2021Frontiers in Medicine
Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?2021Frontiers in Oncology
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)2021Gastroenterology
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis2021Therapeutic Advances in Medical Oncology
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials2021World Journal of Gastroenterology
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer2021The Cochrane Database of Systematic Reviews
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials2021Cancers
Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials2021Bmc Cancer
Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis2021Frontiers in Oncology
Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group2021Journal of Gynecologic Oncology
Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review2021Acta Neurochirurgica
Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials2021Journal of Hepatocellular Carcinoma
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis2021Cancer
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer2021The Cochrane Database of Systematic Reviews
Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials2021Cancers
The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients2021The Oncologist
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review2021Journal of the National Cancer Institute
Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis2020Frontiers in Neurology
Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis2020Translational Cancer Research
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis2020Frontiers in Oncology
Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses2020Aging
Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma2020Medicine
Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis2020Korean Journal of Radiology
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis2020International Journal of Molecular Sciences
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis2020The Cochrane Database of Systematic Reviews
Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials2020Esmo Open
Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment2020Anticancer Research
Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis2020Scientific Reports
Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis2019Scientific Reports
Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis2019Cancers

Clinical Practice Guidelines